BIOMX INC. DL -,0001 Logo
US09090D1037
A2P9A0
PHGE

BIOMX INC. DL -,0001

Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 32,80 € (+27.233,33%). La mediana è 32,80 € (+27.233,33%).

Acquista
  4
Mantieni
  1
Vendi
  0

  • BiomX subsidiary Zorronet launches mobile command app – shares near 52-week low

    Zorronet, a subsidiary of BiomX, has released a mobile app for its command-and-control system on the Google Play Store and Apple App Store. The application aggregates cameras, sensors, drones and IoT data into structured alerts, uses AI for real-time classification and is already in use by cities, regional authorities and Israel Railways. BiomX shares trade at $0.64, close to their 52-week low; the company reports high cash burn, a negative EPS and a weak financial-health rating. Analyst notes point to possible undervaluation, while profitability is not expected this year. » Altro su de.investing.com


  • BiomX approves 2026 equity incentive plan and announces strategy updates

    BiomX shareholders approved the "BiomX Inc. 2026 Equity Incentive Plan," authorizing issuance of up to 1,390,000 common shares and allowing an automatic 4% annual increase over ten years. An adjournment resolution was also adopted but was not needed because sufficient votes were present. BiomX announced an option agreement to acquire DFSL, the appointment of Dr. Ehud Levi to the board, and the amendment of existing warrants (exercise price $1.00, term one year); the NYSE American issued a non‑compliance notice due to insufficient shareholder equity. » Altro su de.investing.com


  • T3 Defense sells ZorroNet to BiomX for shares and promissory note

    T3 Defense’s indirect subsidiary Water IO transferred 100% of ZorroNet to BiomX. In return, BiomX issued 1,300,000 common shares to Water IO (about 16.57% post-transaction) and issued a non-convertible promissory note for USD 1.25 million with a three‑month term; a performance-based earn-out was also agreed, payable by no later than 31 March 2027. ZorroNet provides AI-based computer-vision and autonomous surveillance solutions for defense and critical infrastructure; T3 Defense remains the indirect beneficial owner of the BiomX shares and simultaneously reported further balance-sheet and legal developments. » Altro su de.investing.com

Nel 2022, BIOMX INC. DL -,0001 ha già distribuito 0,26 € di dividendi. L'ultimo pagamento è avvenuto a marzo 2022.

Dati finanziari dell'azienda

Nell'ultimo trimestre, BIOMX INC. DL -,0001 ha registrato ricavi pari a 290,9K € e un utile netto di -3,31 Mln €
(EUR) giu 2026
YoY
Ricavi 290,9K -
Utile lordo 84,99K 134,31%
Utile netto -3,31 Mln 35,47%
EBITDA -3,34 Mln 31,02%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
1,21 Mln €
Numero di azioni
10,15 Mln
Massimo/minimo a 52 settimane
10,61 € - 0,10 €
Dividendi No
Beta
1,37
Rapporto P/E
-0,01
Rapporto PEG
0,00
Rapporto P/B
0,13
Rapporto P/S
4,23

Profilo aziendale

BiomX Inc., ein Mikrobiom-Unternehmen in der klinischen Phase, entwickelt Produkte, die natürliche und künstlich hergestellte Phagen-Technologien nutzen, um bestimmte schädliche Bakterien zu bekämpfen und abzutöten. Es zielt auf Bakterien ab, die das Erscheinungsbild der Haut beeinträchtigen, sowie auf chronische Krankheiten wie entzündliche Darmerkrankungen (IBD), primär sklerosierende Cholangitis (PSC), zystische Fibrose (CF), atopische Dermatitis und Darmkrebs (CRC). Das Unternehmen entwickelt BX004, eine Phagentherapie für Mukoviszidose-Patienten mit chronischen Atemwegsinfektionen durch Pseudomonas aeruginosa, die sich in klinischen Studien der Phase 1b/2a befindet. Zu den Pipeline-Produkten des Unternehmens gehören auch BX005, ein topischer Phagen-Cocktail, der sich in einer klinischen Studie der Phase 1/2 befindet und auf Staphylococcus aureus (S. aureus) abzielt, ein Bakterium, das mit der Manifestation der Krankheit in Verbindung gebracht wird, sowie BX003, ein oral verabreichter Phagen-Cocktail, der sich in der Phase 1b/2a befindet und auf ein bakterielles Ziel abzielt, das im Darm von IBD- und PSC-Patienten vorhanden ist. Darüber hinaus arbeitet das Unternehmen an einem Programm zur Behandlung von Darmkrebs, bei dem speziell entwickelte Phagen mit verschiedenen Nutzlasten eingesetzt werden, die intravenös verabreicht werden, um Bakterien des Typs Fusobacterium nucleatum, die sich in der Mikroumgebung des Tumors befinden, zu bekämpfen. BiomX Inc. wurde 2015 gegründet und hat seinen Hauptsitz in Ness Ziona, Israel.

Nome
BIOMX INC. DL -,0001
CEO
Michael Oster
Sede centrale Dover, de
Stati Uniti
Sito web
Settore
Beni di prima necessità
Industria
Prodotti alimentari
Quotazione in borsa
27/01/2021
Dipendenti 20

Simboli di borsa

Borsa Simbolo
AMEX
PHGE
AMEX
PHGE-UN

Scopri gli asset

Gli azionisti di BIOMX INC. DL -,0001 investono anche nei seguenti asset

🍪

Parqet  usa i cookie. Scopri di più